Signia Therapeutics is an innovative French start-up that specializes in the research and development of antiviral drugs. Established in April 2017 by a team of French and Canadian scientists, Signia Therapeutics has gained recognition for its cutting-edge drug discovery platform. One of their notable achievements is the development of Diltiazem, an anti-hypertensive compound that also exhibits a novel antiviral mechanism of action.

Currently, Diltiazem is being evaluated in a Phase IIb multicentric clinical evaluation for influenza, in combination with oseltamivir (FLUNEXT), and will soon undergo a second Phase IIb trial for mild-to-moderate Covid-19 patients. Signia Therapeutics has been honored with prestigious awards such as the i-Lab 2017 award from the French Ministry of Higher Education, Research and Innovation and the Seal of Excellence from the EU H2020 Framework Programme for Research and Innovation. As a leader in French deeptech, Signia Therapeutics showcases its commitment to innovation and the development of groundbreaking antiviral therapeutics